{"id":"W4322604179","doi":"10.1016/s0140-6736(23)00350-1","title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"Sanofi Genzyme; Genentech; Esperion Therapeutics; Glenmark Pharmaceuticals; BioCryst; Dermira; Regeneron Pharmaceuticals; Galderma; Eli Lilly and Company; Aimmune Therapeutics; CSL Behring; AstraZeneca; Celgene; Sanofi; Torii Pharmaceutical; Amgen","keywords":"Hereditary angioedema; Medicine; Placebo; Internal medicine; Angioedema; C1-inhibitor; Randomized controlled trial; Clinical endpoint; Clinical trial; Adverse effect; Pediatrics; Surgery; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001993298,0.001848955,0.003431817,0.0004289541,0.0004130018,0.001462528,0.0009419799,0.002720332,0.007243804],"category_scores_gemma":[0.001809361,0.0007031052,0.002566781,0.0004401174,0.001533194,0.001305285,0.0004157266,0.003478199,0.001260573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007701413,"about_ca_system_score_gemma":0.001056726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009590795,"about_ca_topic_score_gemma":0.001544643,"domain_scores_codex":[0.999301,0.0003441259,0.00003410101,0.0001406343,0.00005243364,0.0001278098],"domain_scores_gemma":[0.9991479,0.0002857946,0.0001792929,0.00006473501,0.00004785987,0.000274452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805933,0.001810062,0.0003363341,0.0008041104,0.001024408,0.00003410803,0.00003906121,0.0001344316,0.003057558,0.0001122074,0.0009169228,0.01113765],"study_design_scores_gemma":[0.9703863,0.02678453,0.001190503,0.00004642785,0.0005196198,0.00004150478,0.00001542765,0.0001243026,0.0002803442,0.0001279573,0.0004691089,0.00001405431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618952,0.02694809,0.001014145,0.001672888,0.001059662,0.00214718,0.001562469,0.0002336575,0.003466886],"genre_scores_gemma":[0.9788036,0.008214306,0.00156945,0.00261144,0.0005067839,0.00226178,0.001705336,0.00005886948,0.00426846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007243804,"threshold_uncertainty_score":0.02423298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06359225437290582,"score_gpt":0.3624595837101497,"score_spread":0.2988673293372439,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}